The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Interferon-Lambda: A New Addition to an Old Family
Open accessAbstract
The discovery and initial description of the interferon-lambda (IFN-lambda) family in early 2003 opened an exciting new chapter in the field of IFN research. There are 3 IFN-lambda genes that encode 3 distinct but highly related proteins denoted IFN-lambda1, -lambda2, and -lambda3. These proteins are also known as interleukin-29 (IL-29), IL-28A, and IL-28B, respectively. Collectively, these 3 cytokines comprise the type III subset of IFNs. They are distinct from both type I and type II IFNs for a number of reasons, including the fact that they signal through a heterodimeric receptor complex that is different from the receptors used by type I or type II IFNs. Although type I IFNs (IFN-alpha/beta) and type III IFNs (IFN-lambda) signal via distinct receptor complexes, they activate the same intracellular signaling pathway and many of the same biological activities, including antiviral activity, in a wide variety of target cells. Consistent with their antiviral activity, expression of the IFN-lambda genes and their corresponding proteins is inducible by infection with many types of viruses. Therefore, expression of the type III IFNs (IFN-lambdas) and their primary biological activity are very similar to the type I IFNs. However, unlike IFN-alpha receptors which are broadly expressed on most cell types, including leukocytes, IFN-lambda receptors are largely restricted to cells of epithelial origin. The potential clinical importance of IFN-lambda as a novel antiviral therapeutic agent is already apparent. In addition, preclinical studies by several groups indicate that IFN-lambda may also be useful as a potential therapeutic agent for other clinical indications, including certain types of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB regulation in the immune system
Li, Q., & Verma, I. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri910 · Cited by 4,007
CELLULAR RESPONSES TO INTERFERON-γ
Boehm, U., Klamp, T., Groot, M., & Howard, J. C. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.749 · Cited by 2,890
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
AP-1: a double-edged sword in tumorigenesis
Eferl, R., & Wagner, E. F. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1209 · Cited by 2,242
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Kotenko, S. V., Gallagher, G., Baurin, V. V., Lewis-Antes, A., Shen, M., Shah, N. K., Langer, J. A., Sheikh, F., Dickensheets, H., & Donnelly, R. P. (2003) · Nature Immunology · doi:10.1038/ni875 · Cited by 1,868
Self-citationInterferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
Dalton, D. K., Pitts-Meek, S., Keshav, S., Figari, I. S., Bradley, A., & Stewart, T. A. (1993) · Science · doi:10.1126/science.8456300 · Cited by 1,727
IL-28, IL-29 and their class II cytokine receptor IL-28R
Sheppard, P., Kindsvogel, W., Xu, W., Henderson, K., Schlutsmeyer, S., Whitmore, T. E., Kuestner, R., Garrigues, U., Birks, C., Roraback, J., et al. (2003) · Nature Immunology · doi:10.1038/ni873 · Cited by 1,570
Cited by
Immune Signaling by RIG-I-like Receptors
Loo, Y.-M., & Gale, M. (2011) · Immunity · doi:10.1016/j.immuni.2011.05.003 · Cited by 1,875
“…virus infection and signaling through the RLRs also induces the expression of the IFN-l family of IL-10-related cytokines known collectively as type III interferon (IFN-l) (as reviewed in Donnelly and Kotenko, 2010) and various proinflammatory cytokines to control infection (Poeck et al., 2010).”
BackgroundAntitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
The immunogenetics of Psoriasis: A comprehensive review
Harden, J. L., Krueger, J. G., & Bowcock, A. M. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.07.008 · Cited by 616
Zhu, L.-Y., Nie, L., Zhu, G., Xiang, L.-X., & Shao, J.-Z. (2013) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2012.04.001 · Cited by 548
Decoding type I and III interferon signalling during viral infection
Mesev, E. V., LeDesma, R. A., & Ploss, A. (2019) · Nature Microbiology · doi:10.1038/s41564-019-0421-x · Cited by 538
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
Lazear, H. M., Nice, T. J., & Diamond, M. S. (2015) · Immunity · doi:10.1016/j.immuni.2015.07.001 · Cited by 480
The interferons and their receptors—distribution and regulation
de Weerd, N. A., & Nguyen, T. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2012.9 · Cited by 480
Collins, P. L., & Melero, J. A. (2011) · Virus Research · doi:10.1016/j.virusres.2011.09.020 · Cited by 455
Guarding the frontiers: the biology of type III interferons
Wack, A., Terczyńska-Dyla, E., & Hartmann, R. (2015) · Nature Immunology · doi:10.1038/ni.3212 · Cited by 364
Majoros, A., Platanitis, E., Kernbauer-Hölzl, E., Rosebrock, F., Müller, M., & Decker, T. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00029 · Cited by 325
Michalska, A., Blaszczyk, K., Wesoly, J., & Bluyssen, H. A. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01135 · Cited by 322
Induction and function of type I and III interferon in response to viral infection
Levy, D. E., Marié, I. J., & Durbin, J. E. (2011) · Current Opinion in Virology · doi:10.1016/j.coviro.2011.11.001 · Cited by 314
EASL Clinical Practice Guidelines on hepatitis delta virus
Brunetto, M. R., Ricco, G., Negro, F., Wedemeyer, H., Yurdaydin, C., Asselah, T., Papatheodoridis, G., Gheorghe, L., Agarwal, K., Farci, P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.05.001 · Cited by 294
Boisson-Dupuis, S., Kong, X.-F., Okada, S., Cypowyj, S., Puel, A., Abel, L., & Casanova, J.-L. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.04.011 · Cited by 287
The regulation of inflammation by interferons and their STATs
Rauch, I., Müller, M., & Decker, T. (2013) · JAK-STAT · doi:10.4161/jkst.23820 · Cited by 281
Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
Zang, R., Case, J. B., Yutuc, E., Ma, X., Shen, S., Gomez Castro, M. F., Liu, Z., Zeng, Q., Zhao, H., Son, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012197117 · Cited by 240
Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier
Lazear, H. M., Daniels, B. P., Pinto, A. K., Huang, A. C., Vick, S. C., Doyle, S. E., Gale, M., Klein, R. S., & Diamond, M. S. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4304 · Cited by 234
“Whereas IFN-l2 and IFN-l3 are nearly identical (1), IFN-l1 and IFN-l4 may have distinct properties; a polymorphic allele that enables IFN-l4 production is associated with impaired hepatitis C virus clearance (31).”
BackgroundInterferons: role in cancer therapy
Abdolvahab, M. H., Darvishi, B., Zarei, M., Majidzadeh-A, K., & Farahmand, L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0217 · Cited by 50
IL28B, IL29 and micro-RNA 548 in subacute sclerosing panencephalitis as a rare disease
Cakmak Genc, G., Dursun, A., Karakas Celik, S., Calik, M., Kokturk, F., & Piskin, I. E. (2018) · Gene · doi:10.1016/j.gene.2018.07.062 · Cited by 22
Metadata
- Authors
- Donnelly, R. P., & Kotenko, S. V.
- Venue
- Journal of Interferon & Cytokine Research
- Publisher
- SAGE Publications
- Published
- 2010-08
- Volume
- 30
- Issue
- 8
- Pages
- 555-564
- ISSN
- 1079-9907 (ISSN-L)
- 1557-7465
- OpenAlex
- W1973309978
- Cited by
- 420
- References
- 82
- FWCI
- 11.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.